One-Shot Weight Loss: Could Gene Therapy Replace the GLP-1 Revolution?

Dr. Harith Rajagopalan sees the booming market for weight-loss drugs like Wegovy and Ozempic as a multi-billion-dollar bonfire. Millions have turned to GLP-1 agonists to treat obesity and diabetes, but studies show a sobering reality: most patients stop injections within two years, erasing long-term cardiovascular benefits and wasting billions in healthcare spending.

“We are literally lighting tens of billions of dollars on fire,” Dr. Rajagopalan, a cardiologist and co-founder of biotech firm Fractyl Health, told The Washington Post on January 24, referring to the current ‘forever drug’ model.

A High-Stakes Clinical Frontier

Fractyl is taking a bold approach: a gene therapy called Rejuva designed to program the body to produce its own GLP-1 hormone naturally for years after a single infusion. The therapy reportedly uses a proprietary catheter to deliver a harmless virus directly into the pancreas, instructing insulin-producing cells to ramp up GLP-1 production. By producing the hormone locally, Fractyl hopes to avoid the systemic surges that cause nausea and vomiting in patients on current blockbuster drugs.

However, permanence is also the therapy’s greatest risk. Unlike daily pills or weekly shots, gene therapy cannot easily be ‘turned off.’ Giles Yeo, a University of Cambridge genetics professor, warned: “The drugs, you can stop… if you genetically modify someone and they can’t stand it, they’re scr**ed.”

Animal studies suggest a self-limiting mechanism, where lean mice lost less weight than obese mice, but experts caution about unknown long-term effects. Ohio State’s Lei Cao noted that the impact of sustained high GLP-1 levels in the pancreas — an organ not designed as the hormone’s main factory — remains unclear.

Financial and Competitive Landscape

Fractyl positions itself as a ‘David’ among industry Goliaths. While titans like Novo Nordisk and Eli Lilly develop next-generation pills and even more potent shots, Fractyl faces “substantial doubt” about its ability to continue as a going concern, according to regulatory filings.

The company reportedly ended 2025 with enough cash to fund operations through 2026, putting pressure on the upcoming clinical trials for Type 2 diabetes patients. Meanwhile, Wall Street favors ‘gene-lite’ approaches: Wave Life Sciences shares surged 150% in late 2024 after an injectable drug lasting six months showed a 9% reduction in visceral fat. Arrowhead Pharmaceuticals reported similar results with a therapy targeting the INHBE gene, which influences energy storage.

A One-Time Fix for the Insurance Cliff

For many patients, interest in a single-dose therapy is driven by the insurance cliff. Dr. Fatima Cody Stanford of Massachusetts General Hospital told The Washington Post that nearly 70% of her patients lost coverage for GLP-1 drugs this year as insurers balked at high costs.

“Patients are coming off not because they want to, but because they have to,” she said. While she called a long-lasting therapy a potential “cure,” she cautioned, “Would that really happen? This sounds almost too good to be true — and we’ve never seen that to date.”

Fractyl argues that despite the high upfront cost of gene therapy — often in the high six figures to millions — it replaces indefinite pharmacy spending and offers more predictable health outcomes. As the company prepares to seek regulatory clearance for a secondary procedure to regrow healthy gut tissue and begins Rejuva trials, the medical community remains cautiously optimistic.

If successful, Dr. Rajagopalan could not only disrupt a multi-billion-dollar market but also extinguish the unsustainable fire of the current pharmaceutical model.